Page 3 - Tim Oldham News Today

AdAlta Limited , the clinical stage drug discovery company developing novel therapeutic products from its i-body platform, today announced that its CEO and Managing Director, Dr Tim Oldham, would be... | May 30, 2023

AdAlta Ltd (ASX:1AD) managing director Dr Tim Oldham tells Proactive the company’s rights offer has raised A$1.28 million before costs, with commitments in...

From cell therapies and cancer research to COVID-19 and CBD capsules, healthcare stocks are hard at work developing the next generation of diagnostic and...

AdAlta Ltd (ASX:1AD) managing director Dr Tim Oldham tells Proactive the company is seeking an early return to clinical trials of its lead asset, AD-214,...

AdAlta Ltd (ASX:1AD) is seeking an early return to clinical trials of its lead asset, AD-214, with a $3.5 million non-renounceable rights offer. The...

AdAlta Ltd (ASX:1AD) CEO Tim Oldham discusses with Proactive the latest developments with its next generation i-body enabled Chimeric Antigen Receptor...

/PRNewswire/ -- Roots Analysis has announced the addition of "Cell Therapy Manufacturing Market (5th Edition), 2022-2035" report to its list of offerings....

The Healthcare industry is a many-faceted beast, consisting of everything from biotech heart valve replacements to oncolytic cancer-fighting viruses and...

AdAlta Ltd (ASX:1AD) says a new publication by its collaborators at University of Western Australia (UWA) and La Trobe University, published in the peer...

AdAlta Ltd (ASX:1AD) has extended the range and diversity of sequences analogous to its lead program AD-214 with the grant of a second patent in Japan by...